Pfizer, Value Stock
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...
Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...
West Virginia Attorney General (AG) Patrick Morrisey announced a total $17 million settlement agreement with pharmaceutical companies, Pfizer and Ranbaxy after more than a decade of litigation ...
General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...
The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback